Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
GNLX
Strong SellSinkerGenelux Corporation · Healthcare · United States · $120M · Avg Vol: $906K/d
COMPANY DESCRIPTION
Genelux Corporation is a clinical-stage oncology company developing oncolytic immunotherapies for cancer treatment. Its lead product candidate, Olvi-Vec, is a modified vaccinia virus designed to selectively infect and destroy cancer cells while stimulating a systemic anti-tumor immune response. Genelux leverages its proprietary oncolytic virus platform to offer a novel mechanism of action in the challenging cancer therapeutics market, aiming to improve patient outcomes.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 11.1M | 0.2M | 8.0K | 8.0K | -91.0% | 8.0K | — | 8.1M | 3089.5% |
| EPS | -0.22 | -1.16 | -0.95 | -0.86 | — | -0.86 | -0.81 | -0.74 | — |
| Shares | 23.6M | 26.8M | 34.7M | 38.1M | +61.8% | 45.2M | — | — | — |
| Debt | 26.4M | 2.5M | 1.9M | 1.7M | -60.0% | 2.4M | — | — | — |
| Equity | -35.8M | 19.5M | 26.3M | 11.5M | -23.0% | — | — | — | — |
| Op CF | -3.6M | -20.3M | -21.2M | -25.3M | — | -25.3M | — | — | — |
| Inv CF | -49.0K | -14.7M | -8.1M | 12.1M | — | — | — | — | — |
| Fin CF | -0.5M | 44.0M | 28.5M | 9.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GNLX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| GNLX | Genelux Corporation(you) | $120M | 4 | Strong Sell |
| NAUT | Nautilus Biotechnology, Inc. | $113M | 4 | Strong Sell |
| CBUS | Cibus, Inc. | $126M | 2 | Strong Sell |
| ONCY | Oncolytics Biotech Inc. | $109M | 5 | Strong Sell |
| RANI | Rani Therapeutics Holdings, Inc. | $118M | 7 | Strong Sell |
| PLYX | Polaryx Therapeutics, Inc. | $103M | 5 | Strong Sell |
| HURA | TuHURA Biosciences, Inc. | $134M | 6 | Strong Sell |
| INO | Inovio Pharmaceuticals, Inc. | $133M | 3 | Strong Sell |
| NTHI | NeOnc Technologies Holdings, Inc. | $122M | 0 | Strong Sell |
| 2592.HK | Cloudbreak Pharma Inc. | $136M | 1 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.1%